FDA Approves Eylea to Treat Eye Disorder

The safety and effectiveness of Eylea was evaluated in two clinical trials involving 2,412 adult patients. The studies showed that Eylea was as effective as Lucentis in maintaining or improving visual acuity.

The U.S. FDA has approved Eylea (aflibercept) to treat patients with wet (neovascular) age-related macular degeneration (AMD).

AMD gradually destroys a person's sharp, central vision. It affects the macula, the part of the eye that allows people to see fine detail needed to do daily tasks such as reading and driving.

There are two forms of AMD, a wet form and a dry form. The wet form of AMD includes the growth of abnormal blood vessels. The blood vessels can leak fluid into the central part of the retina, also known as the macula. When fluid leaks into the macula, the macula thickens and vision loss occurs.

"Eylea is an important new treatment option for adults with wet A